Dokkyo Medical University, Department of Surgery I , 880 Kitakobayashi, Mibu, Shimotsuga-gun, Tochigi 321-0293, Japan.
Expert Opin Pharmacother. 2013 Jul;14(10):1345-54. doi: 10.1517/14656566.2013.801454. Epub 2013 May 16.
The treatment for esophageal squamous cell carcinoma (SCC) depends on its etiology. For mucosal cancer, endoscopic resection is standard; while for locally advanced cancer, esophagectomy is the main treatment. When the tumor is more advanced, neoadjuvant or adjuvant therapy is added. For unresectable cancer, concurrent chemoradiotherapy is the standard therapy.
The standard chemotherapy for esophageal SCC is a cisplatin- and 5-fluorouracil (CF)-based regimen. Chemoradiotherapy (CRT) is the standard treatment for unresectable esophageal SCC and is also an option for resectable tumors. For patients who are inoperable, concurrent CRT should be the standard of care. Docetaxel, cisplatin and 5-fluorouracil (DCF) therapy is a promising candidate for chemotherapy with or without radiotherapy because an excellent local control rate and pathological remission rate have been reported. Although salvage surgery after definitive CRT is a practical treatment, judicious patient selection is crucial.
Presently, the standard regimen for esophageal SCC is CF. DCF is expected to be the next standard regimen. In the near future, some new therapeutic options, such as molecular targeted therapy or particle beam therapy, may confer further advantages. A thorough understanding of these therapeutic modalities is important to achieve this endeavor.
食管鳞癌（SCC）的治疗取决于其病因。对于黏膜癌，内镜下切除是标准治疗方法；而对于局部晚期癌症，食管切除术是主要治疗方法。当肿瘤更晚期时，会添加新辅助或辅助治疗。对于不可切除的癌症，同步放化疗是标准治疗。
食管 SCC 的标准化疗是基于顺铂和 5-氟尿嘧啶（CF）的方案。放化疗（CRT）是不可切除的食管 SCC 的标准治疗方法，也是可切除肿瘤的一种选择。对于无法手术的患者，同步 CRT 应作为标准治疗。多西紫杉醇、顺铂和 5-氟尿嘧啶（DCF）治疗是一种有前途的化疗方案，无论是否联合放疗，因为已报道其具有良好的局部控制率和病理缓解率。尽管根治性 CRT 后的挽救性手术是一种实用的治疗方法，但明智的患者选择至关重要。
目前，食管 SCC 的标准方案是 CF。DCF 有望成为下一个标准方案。在不久的将来，一些新的治疗选择，如分子靶向治疗或粒子束治疗，可能会带来进一步的优势。彻底了解这些治疗方法对于实现这一目标非常重要。
